Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of choroidal neovascularization in patients with pseudoxanthoma elasticum~* Age between 18-65 years~* Patient must be able to follow protocol~* Written informed consent~* Genetic diagnosis of pseudoxanthoma elasticum~* Best corrected visual acuity between 20/200 - 20/32 in the treated eye~Exclusion Criteria:~* Patients who do not fulfill the inclusion criteria~* Patients with other retinal vascular diseases such as diabetic retinopathy or venous occlusive disease~* Ocular surgery 3 months before study enrollment~* History of uncontrolled glaucoma~* Active intraocular inflammation or inflammation of the ocular adnexa~* Subfoveal fibrosis in the study eye~* Inability to follow study protocol~* Major surgery one month before study enrollment~* History of severe cardiovascular disease or history of stroke 6 months before study enrollment~* Allergies against the substances or components of the study medication~* Low anticipated compliance~* Patients who participated in clinical trials simultaneously or within the last 60 days~* Pregnancy, lactation, women that may become pregnant and don't use safe contraception~* Chronic alcohol- or drug abuse within the last year~* Lacking legal competence or language ability~* Neurologic diseases such as multiple sclerosis~* Need of concomitant medication that is not allowed in combination with ranibizumab~* Previous intravitreal therapy with anti-angiogenic substances in the study eye within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).